In addition to CD33, potential targets identified by proteomic and transcriptomic studies of myeloid cell lines and AML samples include CD123, CD96, CD44, CD47, CD32, CLL‐1, IL1RAP, TIM‐3, and LILRB4 (Dobrowolska et al., 2013; Gasiorowski et al., 2014; Mardis, 2014; Strassberger et al., 2014). The gene discussed is CD33; the disease is acute myeloid leukemia.